T cell immunotherapy can alleviate autoimmune diseases, and the symptoms of improving no medication can reach 17 months

Science and Technology Daily reporter Zhang Mengran

The British "Nature · Medicine" magazine published a health paper that showed five systemic lupus erythematosus patients after CAR-T cell therapy, and no medicine relieved for 17 months.

Car-T therapy successfully relieves systemic lupus erythematosus. Screenshot source: "Nature · Medicine" related papers

Systemic lupus erythematosus (SLE) is an autoimmune rheumatism, with a global population incidence of about 0.1%, high in young women. This lifelong disease is caused by its own antibodies (immune defense molecules attacking its own cells), affecting joints and skin, and may cause severe damage to organs, including kidney, brain, and heart. Most patients are treated with glucocorticoids and B cells for T cells or B cells that produce antibodies. However, these treatments are often invalid, and there are currently no healing therapy.

The CAR-T therapy refers to the cinnamonic antigen receptor T cell immunotherapy. The T, which is T lymphocyte, belongs to a type of white blood cells. With the immune function, CAR is responsible for "positioning navigation" to help identify tumor cells in the body. Therefore, CAR-T therapy can be briefly understood as precise targeted therapy, which is fast and efficient, showing a very good prospect in clinical tumor treatment.

This time, the research team of Ellangen-Nuremberg University in Germany used the transformed anti-CD19 chimeric antigen T cell (CAR) T cells to treat 5 patients with refractory SLE (4 women, 1 male, , Medium Age 22). These cells are designed to remove B cells that produce antibodies by targeting CD19 proteins produced on its surface.

Subsequent (3-17 months after treatment) found that all patients showed improvement of symptoms, including the relief of the burden on the internal organs, and the disappearance of their own antibodies related to disease, and no traditional treatment was required. Common side effects related to CAR-T cell therapy are mild (such as fever), and no infection is observed.

Although these findings may have a new treatment choice for SLE patients, they still need to follow up in larger clinical trials to determine the safety and efficacy of CAR-T cell therapy in this situation.

Circle of the editor -in -chief:

The terminal illness is the most hopeless word in the world. CAR-T therapy has been closely concerned since its birth, because countless desperate people are regarded as "fire". To this day, the therapy has achieved many records and the results of the war are still expanding. For a long time, people's helpless illnesses-cancer or systemic lupus erythematosus in this article are tantamount to burning hope in despair. It is believed that under the huge energy, financial and manpower invested by the medical and scientific community, CAR-T will continue to promote the treatment of difficult and severe illnesses into a new era.

- END -